Skip to main content

  • Early Data Suggest Edwards' Fourth-Generation SAPIEN 3 Ultra Valve Further Minimizes PVL in TAVR

    • Posted: 10/28/2020
    • Author:

      Giorgio A. Medranda, CRTonline.org

    • News

    Initial data from a German registry suggest that transcatheter aortic valve replacement (TAVR) using the SAPIEN 3 Ultra (Edwards Lifesciences, Irvine, California) had similar short-term outcomes, but significantly less mild paravalvular leak (PVL), in comparison with the SAPIEN 3 transcatheter heart valve (THV).

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details